5:19 PM
 | 
Aug 19, 2009
 |  BC Extra  |  Clinical News

Gentium falls on defibrotide data

Gentium S.p.A. (NASDAQ:GENT) fell $0.42 (12%) to $2.98 on Wednesday after top-line data from an open-label Phase III trial to treat severe veno-occlusive...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >